Teleflex Incorporated reports developments for a global medical technology business that supplies hospitals and healthcare providers with devices used in anesthesia, emergency medicine, interventional cardiology and radiology, surgery, vascular access and urology. Its established brands include Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift and Weck.
Recurring Teleflex news covers quarterly financial results, outlook updates, revenue trends by global product category, portfolio realignment and integration of acquired vascular intervention assets. Company updates also include governance and leadership changes, board committee matters, capital allocation actions, shareholder communications and operational initiatives such as integrated demand and supply planning.
Teleflex (TFX) reported an association between Arrowg+ard catheters and a 70% lower bloodstream infection hazard in a published study.
The prospective study, published in the American Journal of Infection Control, included 1,750 critically ill patients at six hospitals in four countries. Over 30 days, catheters protected with Arrowg+ard Technology were associated with lower central line-associated bloodstream infection (CLABSI) hazard than plain catheters (hazard ratio 0.297; 95% confidence interval 0.134–0.658; p=0.003). Mortality was 18.4% in the chlorhexidine/silver sulfadiazine catheter group versus 28.3% in the plain-catheter group. A 2025 study reported a 70.5% reduction in overall CLABSI incidence.
Nyxoah (NYXH) appointed Liam Kelly chief executive officer effective October 1, 2026, succeeding Olivier Taelman.
Nyxoah links the change to its shift toward U.S.-focused commercialization following FDA approval and the U.S. launch of its Genio sleep apnea treatment. Kelly served as president and CEO of Teleflex (TFX) from January 2018 until January 2026 and as its chairman from May 2020 until January 2026. He is also a director of Enovis (ENOV).
Teleflex (TFX) appointed veteran medical technology executive Sean M. Salmon to its Board of Directors, effective September 8, 2026.
Salmon brings over 30 years of global leadership experience in medical devices and pharmaceuticals, including more than 20 years at Medtronic (MDT), where he most recently served as Executive Vice President and President of the Cardiovascular Portfolio, a business with fiscal 2025 revenue of approximately $12.5 billion. He has also led Medtronic’s Diabetes, Coronary and Structural Heart, and Coronary and Renal Denervation businesses and currently serves as an independent director of Adagio Medical Holdings (ADGM).
With his appointment, the Teleflex Board now has nine directors, eight of whom are independent, and one third of the Board has been refreshed in 2026. Salmon will also join the Board’s Growth and Operating Committee, which was created to support Teleflex’s strategic transformation and operational execution.
Teleflex (TFX) will feature its Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026 in Copenhagen, highlighting trans-radial iliac interventions.
The device is supported by the investigator-initiated BIONETIC-TRA study (N=25, 30-day follow-up), which evaluated safety and feasibility for treating atherosclerotic iliac artery lesions via radial access. The study reported a 100% procedural success rate with the Dynetic™-35 Stent and a low rate of asymptomatic radial artery occlusion. The stent system, constructed from cobalt chromium with proBIO™ Coating, offers high radial strength, compatibility with 6F delivery systems and usable lengths up to 170 cm. Dynetic™-35 is distributed in selected countries and is not approved for sale in the United States, with indications varying by geography.
Teleflex (NYSE: TFX) announced that its Board of Directors has declared a quarterly cash dividend of $0.34 per share on its common stock. The dividend will be payable on September 30, 2026 to shareholders of record as of the close of business on August 14, 2026.
Teleflex (NYSE: TFX) reported second quarter 2026 revenue from continuing operations of $570.3 million, up 28.9% year over year and 4.7% on a pro forma adjusted constant currency basis. GAAP diluted EPS from continuing operations was $0.96 versus $1.54, while adjusted diluted EPS rose to $1.76 from $1.73.
The company completed the $1.5 billion cash divestiture of its OEM business, estimating $1.25 billion after-tax proceeds, and repaid a $700 million Term Loan A-2. Teleflex repurchased 1.9 million shares for $250 million in Q2 and plans a further $250 million accelerated share repurchase starting August 7, 2026, under its $1 billion authorization.
Full-year 2026 guidance for GAAP revenue growth from continuing operations was reduced to 13.4%–14.4% and pro forma adjusted constant currency growth to 3.5%–4.5%. GAAP EPS guidance was lowered to $2.54–$2.84, while adjusted EPS guidance increased to $6.90–$7.20. The company highlighted FDA BLA approval for EZPLAZ freeze-dried plasma and continued advancement of the Freesolve clinical program.
Teleflex (NYSE:TFX) has completed the previously announced divestiture of its OEM business to Montagu and Kohlberg for $1.5 billion in cash. According to Teleflex, it expects after-tax proceeds of approximately $1.25 billion from the transaction.
The company intends to use the net proceeds to support its stated capital allocation priorities, including reducing debt by $800 million and completing its $1 billion share repurchase authorization. Teleflex said the divestiture is a key step in its transformation strategy, enhancing financial flexibility and focusing on commercial excellence in its remaining businesses. Updated 2026 financial guidance is expected when second-quarter results are reported on August 6, 2026.
Teleflex (NYSE: TFX) announced that the U.S. FDA has granted Biologics License Application (BLA) approval for EZPLAZ™ Freeze Dried Plasma (FDP), the first FDA-licensed freeze dried plasma and the company’s first biologics license for a blood component.
EZPLAZ™ FDP is indicated for transfusion in adults when plasma is required and other plasma products are not available, including uncontrolled hemorrhage, massive transfusion, liver disease, disseminated intravascular coagulation, and urgent warfarin reversal. The product uses a patented flexible plastic bag rather than glass bottles, is supplied with Sterile Water for Injection, can be stored at 2–25°C with a 12‑month shelf life, and reconstitutes in about 1–2.5 minutes. Development was supported through a Cooperative Research and Development Agreement with the Defense Health Agency’s Warfighter Protection and Acute Care team, targeting battlefield and prehospital use where traditional plasma logistics are challenging.
Teleflex (NYSE:TFX) will host a conference call to discuss its second quarter 2026 financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, August 6, 2026. Investors can participate by pre-registering via a provided link to receive dial-in details or by listening to a live audio webcast on teleflex.com.
An audio replay will be available from 11:00 a.m. Eastern Time on August 6, 2026, on the Teleflex website or by phone at 1 800 770 2030 (U.S./Canada) or 1 609 800 9909 (other locations), using conference ID 69028.
Teleflex (NYSE: TFX) has been awarded a national group purchasing agreement for central venous access products with Premier, effective July 1, 2026. The agreement enables Premier members, at their discretion, to access pre-negotiated pricing and terms on select Teleflex vascular access products, including short-term central venous catheters, arterial catheters, and Arrow™ EZ-IO™ intraosseous access systems.
Premier members gain access to a broad Arrow™ portfolio such as Arrowg+ard Blue Plus™ central venous catheters, ErgoPack™ complete systems, multi-lumen access catheters, and percutaneous sheath introducers, aimed at supporting evidence-based vascular access practices, standardization, workflow efficiency, and management of infection-related risks.